top of page

Sparian Biosciences

Harnessing the diversity of gene processing

Sparian Biosciences is a bio-pharmaceutical company focusing on discovering and developing new therapies which target the central nervous system (CNS).

Top of Page

About

Sparian Biosciences is a bio-pharmaceutical company focusing on discovering and developing new therapies which target the central nervous system (CNS).

The treatment of CNS diseases, such as pain, addiction and psychological disorders, has seen no true pharmaceutical innovation in years.

Sparian was co-founded by Gavril Pasternak, MD PhD and Jeff Reich, MD after the Pasternak Lab discovered a novel new analgesic (e.g. pain killer) with better pain relief than morphine while minimizing the adverse side effects that cause other opioids.

Through groundbreaking research, innovative thinking and expert collaboration, our company feels we could change the way CNS diseases are treated on a global scale.

To learn more, click below

About
Our Team

Our Team

Jeff head Shot.jpg

Jeff Reich

MD

Chief Executive Officer

Co-founder

Introduce your team! Click here to add images, text and links, or connect data from your collection.

Gav Photo.jpg

Gavril Pasternak

MD, PhD

Scientific and Company

Co-founder

Anne Burnett Tandy Chair of Neurology

Member and Laboratory Head Molecular Pharmacology Program and Department of Neurology at MSK

 

Professor of Neurology, Neuroscience, Pharmacology and Psychiatry at Weill Cornell Medical College

Pan.jpg

Ying-Xian Pan

MD, PhD

Scientific Co-Founder

Attending, and Member

Department of Neurology at MSKCC

DSC_6702.jpg

Anna Pasternak

Chief Business Officer

Introduce your team! Click here to add images, text and links, or connect data from your collection.

Sush Photo.png

Susruta Majumdar

PhD

Scientific Co-Founder

Associate Professor of Pharmacology and Pharmaceutical Sciences

Center for Clinical Pharmacology

St. Louis College of Pharmacy

Washington University School of Medicine

St. Louis, MO

Pipeline

Arylepoxamides

Arylepoxamides are a new class of drugs which have been found to bind the newly discovered AEAr receptors.

Precision Neuropsychiatry

Make this yours. Add images, text and links, or connect data from your collection.

Mitragynine Derivatives

Make this yours. Add images, text and links, or connect data from your collection.

Pipeline
bottom of page